Sanofi-Aventis engages in the research, development, manufacture, and marketing of healthcare products worldwide. It offers products in various therapeutic fields, including cardiovascular, thrombosis, oncology, metabolic disorders, central nervous system, and internal medicine and vaccines. The company’s products include Plavix, an anti-platelet agent for various atherothrombotic conditions; Lovenox, a low molecular weight heparin indicated for prophylaxis and treatment of deep vein thrombosis, and for unstable angina and myocardial infarction; Aprovel and Tritace for hypertension treatments; Lantus, an analog insulin and Amaryl, a sulfonylurea for metabolic disorders; Acomplia for obese or overweight patients with type 2 diabetes or dyslipidemia risk factors; Taxotere, a taxane derivative representing a therapy in various cancer types; and Eloxatine, a platinum agent for treating colorectal cancer. It offers Stilnox /Ambien CR, an insomnia prescription medication; Copaxone, an immunomodulating agent indicated in multiple sclerosis; Depakine, an epilepsy treatment; Allegra, a non-sedating prescription antihistamine; Nasacort, a corticosteroid indicated in allergic rhinitis; Xatral for benign prostatic hypertrophy; and Actonel for osteoporosis. The company also offers generic drugs, including prescription drugs, and products sold over the counter through its brand Winthrop. Its human vaccines activity offers pediatric combination vaccines that provide protection against diseases, such as pertussis, diphtheria, tetanus, and haemophilus influenzae type b infections. The company also provides poliomyelitis vaccines; oral polio formulations; influenza vaccines; influenza vaccines; adult and adolescent booster vaccines; meningitis vaccines; and travel, endemic and measles, mumps, and rubella (MMR) vaccines. Sanofi-Aventis has strategic collaboration agreement with Regeneron Pharmaceuticals, Inc. The company was founded in 1970 and is headquartered in Paris, France.